Neurogene Inc. — Operating Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/16ac0e33-d993-4de9-aa71-f7307453ea2c/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-103.3M | 2025-01-01 – 2025-12-31 | evidence 0001404644-26-000019 |
| FY 2024 | $-82.6M | 2024-01-01 – 2024-12-31 | evidence 0001404644-25-000012 |
| FY 2023 | $-55.6M | 2023-01-01 – 2023-12-31 | evidence 0001404644-24-000020 |
| FY 2022 | $-56.5M | 2022-01-01 – 2022-12-31 | evidence 0001404644-24-000020 |
| FY 2021 | $-60.7M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-004491 |
| FY 2020 | $-33.7M | 2020-01-01 – 2020-12-31 | evidence 0001628280-21-005630 |
| FY 2019 | $-71.0M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-071545 |
| FY 2018 | $-32.6M | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-066506 |
| FY 2017 | $-51.1M | 2017-01-01 – 2017-12-31 | evidence 0001193125-19-066506 |
| FY 2016 | $-37.6M | 2016-01-01 – 2016-12-31 | evidence 0001193125-19-066506 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).